Ziresovir is the first antiviral to demonstrate significant clinical efficacy and long-term respiratory benefits in ...

Ziresovir's Phase III results mark a significant milestone, representing the first clinical validation of an antiviral's ...

The Lancet Child & Adolescent Health, a leading international journal in pediatric and adolescent medicine, has published the ...

As millions of Brits battle runny noses, croaky coughs and watery eyes, it may be easy to chug an antihistamine, but the nation is also known for a series of common viruses this time of year.

Adults suffering from respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) face a nearly threefold ...

ONE of the UK’s most common bugs almost triples the risk of death for a year after infection, scientists have discovered. For ...

From Covid to HMPV and flu, it’s peak season for many viruses – here are the symptoms to look out for and the best way to ...

The Allan Labor Government is keeping Victorian babies safe from Respiratory Syncytial Virus (RSV) this winter, with a long-acting immunisation available free from tomorrow for eligible families until ...

A 2023–24 vaccine effectiveness analysis of immunocompetent adults aged 60 years or older in the USA showed 80% (95% CI 71–85) protection against respiratory syncytial virus (RSV)-associated hospital ...

In a recent final analysis of a phase 3 trial, the bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine maintained high efficacy and a favorable safety profile against RSV-associated ...